Where Is Cannabis Legal? A Guide To All 50 States

Key Concepts

• Cannabis Rescheduling: The potential reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act.
• Schedule I vs. Schedule III Drugs: Understanding the legal and regulatory differences between these classifications.
• Hemp Intoxicating Industry Ban: The amendment proposed by Senator Mitch McConnell impacting the sale of intoxicating hemp products.
• State-Level Legalization Efforts: Ongoing attempts to legalize recreational and medical cannabis in various states.
• Federal vs. State Law Conflict: The ongoing tension between federal prohibition and state-level legalization.

Cannabis Legalization Landscape: A 50-State Guide (2025-2026)

The cannabis industry experienced a significant, albeit complex, period at the close of 2024 and looking into 2025-2026. While a potential federal shift in classification offered a glimmer of hope, challenges persist at both the federal and state levels.

Federal Developments: Rescheduling and Hemp Regulations

In late December 2024, President Donald Trump signed an executive order directing the Attorney General to initiate the marijuana rescheduling process “in the most expeditious manner.” This aims to reclassify marijuana from a Schedule I drug – alongside heroin and LSD – to a Schedule III drug. Schedule III includes substances with accepted medical benefits but potential for addiction, such as steroids, ketamine, and Tylenol with codeine.

This rescheduling will not legalize cannabis federally. However, it is projected to provide the $32 billion cannabis industry with a substantial tax benefit, potentially worth billions of dollars. Despite this, the process is expected to be lengthy, and restrictions on manufacture, sales, and possession will remain. The current timeline is uncertain, as Attorney General Pam Bondi has not publicly commented on the process.

Conversely, 2025 brought a setback for the hemp industry. Senator Mitch McConnell’s amendment to a spending bill effectively bans the sale of intoxicating hemp products, set to take effect in November unless new legislation is enacted. This impacts the $28 billion intoxicating hemp industry.

State-Level Challenges to Cannabis Sales

Alongside federal uncertainty, several states face obstacles to expanding or maintaining cannabis sales. Well-funded campaigns are underway in Arizona, Massachusetts, and Maine to repeal existing recreational cannabis sales. Furthermore, opposition to federal rescheduling has materialized, with a group hiring former Attorney General Bill Barr to potentially file a lawsuit should the rescheduling process be finalized by Attorney General Bondi.

Paul Armentano, Deputy Director of NORML, expressed limited optimism regarding further state-level legalization, stating, “I do not have a lot of optimism at this point when it comes to more states legalizing,” and adding, “looking forward, I’m not convinced the prospects are strong for this year.”

Potential Expansion: State-by-State Outlook (2026)

Despite the challenges, several states are considering cannabis legalization:

• Florida: A ballot measure to legalize recreational marijuana failed to pass in 2024, despite President Trump’s support, falling short of the required 60% vote. It may return to the ballot in November 2026.
• Hawaii: The first state to legalize medical marijuana via legislation in 2000, Hawaii has struggled to establish a recreational market. A current push aims to get the issue on the ballot.
• Pennsylvania: Governor Josh Shapiro supports recreational legalization, and all bordering states (excluding West Virginia, which has a limited medical program) have already legalized adult use. Previous efforts have stalled.
• Virginia: Recreational marijuana was legalized in 2021, but a legal market has not been established due to vetoes from former Governor Glenn Youngkin. Newly elected Governor Abigail Spanberger has pledged to sign a bill allowing sales, contingent on strong labeling provisions and dedicated tax revenue for education funding.

Federal-State Conflict & Current Legal Status

Currently, 40 states allow medical sales, and 25 permit recreational sales. However, this patchwork of state regulations remains in conflict with federal law, as marijuana remains a Schedule I substance. This discrepancy creates ongoing legal and financial complexities for the industry.

This information is based on reporting by Will Yakawitz on Forbes.com.